<DOC>
	<DOCNO>NCT00192049</DOCNO>
	<brief_summary>Gemcitabine show highly effective well tolerate first second line therapy , single agent combination therapy treatment metastatic transitional cell carcinoma . On basis Gemcitabine clinical activity good tolerability drug recently test intravesical therapy . consider Gemcitabine good therapy candidate patient intermediate risk superficial bladder cancer . Based phase I/II clinical trial w go explore efficacy tolerability Gemcitabine setting , compare Mitomycin C widely use group patient .</brief_summary>
	<brief_title>A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C Patients With Intermediate Risk Superficial Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>Histologically verify superficial transitional cell carcinoma bladder . patient primary recurrent intermediate risk superficial bladder cancer TUR . Patients primary tumor stage TaG1 multiple lesion ( &gt; 3 ) lesion big 3 cm patient TaG23 T1G12 . Patients must pretreated intravesical immunotherapy ( BCG ) chemotherapy . Male female , age great 18 . Time TUR start intravesical chemotherapy longer 4 week . Patients receive previous ( BCG ) chemotherapy . Patients evidence invasive , locally advanced metastatic bladder cancer ( great equal T2 disease ; stage great equal B1 ) patient upper urinary tract disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>